CONTACT US


Hotline:400-880-6268
 
Hefei Management Center

Address: Jinmei Road.shuangFeng Development Zone,Hefei,Anhui Province

Phone:0551-66396747

Fax:0551-66396757
 
Kayaku base
Address: Jinmei Road.shuangFeng Development Zone,Hefei,Anhui Province
Tel: 0551-66396747
 
 
 
品簡介Product Introduction
Your current location:Home > Products > Product Introduction
Allopurinol Tablets
Name: allopurinol tablets

Ingredients: The main ingredients allopurinol, the chemical name for the 1H- pyrazolo [3,4-d] pyrimidine-4-ol

Category: anti-gout drug

Drug Classification: Chemicals, National Essential Drug

Indications: For ① primary and secondary hyperuricemia, especially caused by excessive uric acid production hyperuricemia; ② recurrent or chronic gout; ③ tophi; ④ uric acid kidney stones and (or) uric acid nephropathy; ⑤ renal dysfunction hyperuricemia.

Approval Number: H34021248 Zhunzi

Specification: 100mg per tablet

Packaging: plastic bottles, 100 tablets/bottle

Storage: sealed to store at room temperature

Duration: 24 months

Allopurinol tablets instructions: Please read the instructions carefully and use under the guidance of doctors. [Drug Name] Generic Name: Allopurinol tablets Ingredient] the main ingredients of allopurinol, its chemical name 1H- pyrazolo [3,4-d] pyrimidin-4-ol. Chemical Structure: Formula: C5H4N4O Molecular Weight: 136.11 [Character] white Indications for ① primary and secondary hyperuricemia, especially caused by excessive uric acid production hyperuricemia; ② recurrent or chronic gout; ③ tophi; ④ uric acid kidney stones and (or) uric acid nephropathy; ⑤ renal dysfunction hyperuricemia. [Specification] 0.1g [Dosage and oral ] (1) Adult usual dose: initial dose once 50mg (half tablet), 2 times for one day . Every week may be incremented 50 ~ 100mg (half sheet - 1), to the day 200 ~ 300mg (2 tablets ~ 3), 2 to 3 times service. Every two weeks and blood uric acid levels measured , once has reached normal levels, patients are no longer increase dose. But one day the maximum amount shall not exceed 600mg (6 pieces). (2) the treatment of children with secondary hyperuricemia use common dose: less than 6 years old each 50mg (half tablet), 1 to 3 times a day; 6 to 10 years old, 100mg one time(1 tablet), 1 to 3 times a day . The dose may be adjusted as appropriate. Side effects (1) Rash: can be presented pruritic papules or urticaria. If rash widespread and long-lasting must be discontinued. (2) gastrointestinal reactions include: diarrhea, nausea, vomiting and abdominal pain. (3) neutropenia, or thrombocytopenia, or anemia, or bone marrow suppression, should consider stopping. (4) Other hair loss, fever, swollen lymph nodes, liver toxicity, interstitial nephritis and allergic vasculitis. (5) have been reported in the number of foreign patients taking this medicine occurred the sudden death of unknown cause. (6) It can cause exfoliative dermatitis, toxic epidermal necrolysis, liver damage, kidney damage. Taboo : allergy, liver ,kidney dysfunction and significantly lower blood cells were banned to use. [Note] (1) This product can not control acute inflammation of gouty arthritis symptoms, not as an anti-inflammatory drug use. Because this product is to promote re-dissolve uric acid crystals can induce and aggravate arthritis and symptoms again. (2) This product must begin to use when gouty arthritis inflammation symptoms disappear (usually about two weeks after the attack) (3) After take the medication should should be drink more water in order to the urine become the neutral or alkaline. It is good to facilitate the excretion of uric acid. (4) Then medicine should not be used to promote excretion of uric acid if people who has blood uric acid, tophi, or urinary stones . (5) The product must start from small dose and gradually increased to an effective amount to maintain normal serum uric acid and uric acid levels, then gradually reducing to minimum effective dose for lasting longer . (6) with uricosuric medicine can enhance the efficacy. Not good with the chalybeate. (7) before treatment and periodically during treatment to check the blood uric acid and uric acid levels of 24 hours, as the basis for dose adjustment. (8) should reduce the daily dose if people who has kidney, liver dysfunction. and the elderly should be careful medication, (9) Should be checked regularly the blood and liver and kidney function during medication using (10) If there are any signs of skin reactions or other hypersensitivity reactions should be immediately discontinued and go to emergency room get the treatment; should reduce the dose ;If people have kidney or liver damage. If people have renal dysfunction, should adjust the dose base one creatinine clearance rate. Pregnant women and lactating women use : not allowed Pediatric Use: Children dosage should be adjusted as appropriate. Geriatric Use: the elderly should be careful medication and reduce the daily dose. Drug interactions (1) drinking, chlorthalidone, ethacrynic acid, furosemide, metolazone, pyrazinamide or thiazide diuretics may increase serum uric acid. When control gout and hyperuricemia, should pay attention to adjusting dosage.It has reported that when using this product with thiazide diuretics may cause the emergence of allergies, if patients with hypertension or renal dysfunction. (2) The goods and ampicillin with the use of increased incidence of rash, especially in patients with hyperuricemia. (3) The goods and anticoagulant drugs such as dicoumarol and indandione derivatives are using together. the effect of anticoagulant drugs can enhance better. However ,should pay attention to adjust the dose. (4)when using the product with azathioprine or mercaptopurine, with the latter one should generally reduce the amount of 1/4 to 1/3. (5) The goods and cyclophosphamide with the use of bone marrow suppression may be more obvious. (6) The goods and uric acid with the use of drugs, may increase the formation of kidney stones. (7) has been reported that patients should be careful to use it if patients with chronic renal failure allopurinol tablets and captopril angiotensin-converting enzyme inhibitor Over-dosage: no reliable references, please ask doctor. Pharmacological inhibition of uric acid synthesis This product is a drug. Allopurinol and its metabolites oxygen allopurinol inhibited xanthine oxidase, hypoxanthine and xanthine prevent uric acid metabolism, thereby reducing the production of uric acid. The blood and urine levels of uric acid solubility is reduced to the following levels, prevent the formation of crystals of uric acid is deposited in the joints and other tissues, but also help patients with gout uric acid crystals within the organization to re-dissolve. New purine synthesis in vivo inhibition of guanine nucleic acid phosphatase converting enzymes - allopurinol also by hypoxanthine. This product is 24 hours after oral administration of serum uric acid concentration began to decline, and in 2 to 4 weeks and it decreased significantly. Acute toxicity test results: oral LD50 in rats of 6000mg / kg, intraperitoneal injection of LD50 of 750mg / kg; mouse oral LD50 of 700mg / kg, intraperitoneal injection of LD50 of 160mg / kg. Pharma-cokinetics: This product is completely absorbed after oral administration, from 2 to 6 hours up to the peak plasma concentration in the gastrointestinal tract, liver metabolism in active oxygen allopurinol, both of which can not be bound to plasma proteins. Half-life of this product is 14 to 28 hours, and oxygen allopurinol by the kidneys. With uricosuric drugs can promote oxygen allopurinol excretion, renal insufficiency but reduce their emissions. [Storage] shading, sealed and stored. [Packing] plastic bottles, each bottle of 100. [Validity] 24 months Bipartite [Executive standard] "Chinese Pharmacopoeia" 2010 edition [Approval No.] H34021248 Zhunzi Manufacturer Company Name: Hefei Jiulian Pharmaceutical Co., Ltd. Address: Hefei Shuangfeng Economic Development Zone Postal Code: 231131 Telephone: 0551-66396747 Fax: 0551-66396757

   Manager: Shuangfeng Development Zone, Hefei, Anhui Jin Mei Road                                            News center---- Show Information、Company News

     

 

 Copyright@2009 Hefei long lian pharmaceutical co.,·All rights reserved, ICP for 12000624     service hotline :0551-66396747

 

The Internet drug information service qualification certificate of the People's Republic of China (ji) - non-operating - 2013-0001 技術支持:合肥網絡公司 謹宸網絡

 

日本a级黄毛片免费_日本a级黄毛片免费天堂_日本a级视频在线播放